Demonstrating biosimilar and originator antidrug antibody binding comparability in antidrug antibody assays: a practical approach
2017
Biosimilar
drug developmenthas brought new challenges to bioanalytical
ligand-binding assaysused to determine drug concentration, antidrug antibodies and
neutralizing antibodies. One particular challenge is how to demonstrate that the antidrug antibody assay can adequately detect antibodies against both
biosimilarand originator. In this paper, we review the current guidelines and literature for practical recommendations and present a gap analysis. Case examples of antibody binding comparability testing are presented, and the challenges and implications are discussed. Based on the lessons learned from our
biosimilarassay applications, we recommend a bioanalytical comparability testing approach that is outlined and discussed.
Keywords:
-
Correction
-
Source
-
Cite
-
Save
14
References
8
Citations
NaN
KQI